Pulse Biosciences enrolls first patients in PRECISE-BTN study for benign thyroid nodules

PULSE BIOSCIENCES, INC.

First successful procedures using nsPFA Percutaneous Electrode System for benign thyroid nodules (BTNs).
Multicenter IRB-approved study will enroll up to 50 patients across four sites.
Endpoints include safety, nodule volume reduction, symptom relief, quality of life, and cosmesis at 1, 3, 6, 12 months.
CEO notes ongoing commercial launch pilot phase alongside clinical study progression.
Principal investigator reports early positive results and organ-sparing potential.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.